FrancophonIA/ELRC3.0 huggingface dataset:
English: The active substance in Tovanor Breezhaler, glycopyrronium bromide, is a muscarinic receptor antagonist.
Estonian: Tovanor Breezhaleri toimeaine glükopürrooniumbromiid on muskariiniretseptori antagonist, mis blokeerib kopsulihaste muskariiniretseptorid, mistõttu bronhid laienevad.
English: In all three studies, Parsabiv was given for 26 weeks.
Estonian: Kõigis kolmes uuringus kasutati Parsabivi 26 nädalat.
English: What measures are being taken to ensure the safe and effective use of Parsabiv?
Estonian: Mis meetmed võetakse, et tagada Parsabivi ohutu ja efektiivne kasutamine?
English: The full EPAR for Parsabiv can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Parsabivi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What is Parsabiv and what is it used for?
Estonian: Mis on Parsabiv ja milleks seda kasutatakse?
English: The main measure of effectiveness was a reduction in parathyroid hormone by more than 30% after at least 20 weeks of treatment.
Estonian: Efektiivsuse põhinäitaja oli parathormoonisisalduse vähenemine rohkem kui 30% võrra vähemalt 20-nädalase ravi järel.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Parsabiv's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Inimravimite komitee otsustas, et Parsabivi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: Other information about Parsabiv
Estonian: Muu teave Parsabivi kohta
English: Why is Parsabiv approved?
Estonian: Miks Parsabiv heaks kiideti?
English: What are the risks associated with Parsabiv?
Estonian: Mis riskid Parsabiviga kaasnevad?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Parsabiv have been included in the summary of product characteristics and the package leaflet.
Estonian: Parsabivi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: In the first two studies, Parsabiv was effective in 75% (380 out of 509) of patients compared with 9% (46 out of 514) of patients given placebo.
Estonian: Esimeses kahes uuringus oli efektiivse toimega patsiente Parsabivi uuringurühmas 75% (380 patsienti 509st) ja platseeborühmas 9% (46 patsienti 514st).
English: It is not intended to provide practical advice on how to use Parsabiv.
Estonian: Hindamisaruandes ei anta Parsabivi kasutamise praktilisi nõuandeid.
English: Parsabiv must not be started if the patient's blood calcium level is below the normal range.
Estonian: Parsabiviga toimuvat ravi ei tohi alustada, kui patsiendi vere kaltsiumisisaldus on normaalvahemikust väiksem.
English: Treatment is started at a dose of 5 mg three times a week and the dose is then adjusted according to the patient's parathyroid hormone level or calcium level.
Estonian: Annus ravi alguses on 5 mg kolm korda nädalas ja seejärel kohandatakse annust patsiendi vere parathormooni- või kaltsiumisisalduse järgi.
English: The most common side effects with Parsabiv (which may affect more than 1 in 10 people) are low calcium level in the blood, muscle spasm, diarrhoea, nausea (feeling sick) and vomiting.
Estonian: Parsabivi kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on vere väike kaltsiumisisaldus, kõhulahtisus, iiveldus ja oksendamine.
English: The first two studies compared Parsabiv with placebo (a dummy treatment), and the third study compared it with cinacalcet, another calcimimetic medicine.
Estonian: Esimeses kahes uuringus võrreldi Parsabivi platseeboga (näiv ravim) ja kolmandas uuringus tsinakaltseediga (samuti kaltsimimeetiline ravim).
English: In the third study, Parsabiv was found to be at least as effective as cinacalcet: in 68% (232 out of 340) patients given Parsabiv compared with 58% (198 out of 343) patients given cinacalcet.
Estonian: Kolmandas uuringus oli Parsabiv vähemalt sama efektiivne kui tsinakaltseet: efektiivse raviga patsiente oli Parsabivi uuringurühmas 68% (232 patsienti 340st) ja tsinakaltseedi uuringurühmas 58% (198 patsienti 343st).
English: For practical information about using Parsabiv, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Parsabivi kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: For the full list of Parsabiv's side effects and restrictions, see the package leaflet.
Estonian: Parsabivi kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: Parsabiv etelcalcetide
Estonian: Parsabiv etelkaltsetiid
English: Parsabiv has been investigated in three main studies involving 1,706 patients on haemodialysis who had long-term kidney disease and secondary hyperparathyroidism.
Estonian: Parsabivi on uuritud kolmes põhiuuringus, kus osales 1706 kroonilise neeruhaiguse tõttu hemodialüüsravi saavat ja sekundaarse hüperparatüreoidismiga patsienti.
English: How is Parsabiv used?
Estonian: Kuidas Parsabivi kasutatakse?
English: Parsabiv is a medicine used to reduce the levels of parathyroid hormone in adults who have high levels of this hormone because of their long-term kidney disease (secondary hyperparathyroidism).
Estonian: Parsabiv on ravim, mida kasutatakse kõrvalkilpnäärmehormooni (parathormooni) sisalduse vähendamiseks täiskasvanutel, kellel selle hormooni sisaldus on kroonilise neeruhaiguse tõttu suurenenud (sekundaarne hüperparatüreoidism).
English: This is a summary of the European public assessment report (EPAR) for Parsabiv.
Estonian: See on ravimi Parsabiv Euroopa avaliku hindamisaruande kokkuvõte.
English: Parathyroid hormone is produced by the parathyroid glands in the neck and regulates calcium and phosphate levels.
Estonian: Parathormoon tekib kaelas paiknevates kõrvalkilpnäärmetes ning see hormoon reguleerib kaltsiumi- ja fosfaadisisaldust.
English: For more information about treatment with Parsabiv, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Parsabiviga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: It contains the active substance etelcalcetide.
Estonian: Parsabivi sisaldab toimeainena etelkaltsetiidi.
English: High levels of parathyroid hormone can cause loss of calcium from the bones, bone pain and fractures, and heart and circulation problems.
Estonian: Parathormooni suur sisaldus põhjustab kaltsiumi kadumist luudest, luuvalu ja -murde ning südame ja vereringe probleeme.
English: How does Parsabiv work?
Estonian: Kuidas Parsabiv toimib?
English: What benefits of Parsabiv have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Parsabivi kasulikkus?
English: In some circumstances, it can be given by injection into a vein.
Estonian: Teatud tingimustel tohib Parsabivi manustada ka veenisisese süstena.
English: The medicine has been found effective for reducing parathyroid hormone in the blood in patients with kidney disease being treated with haemodialysis and its side effects are those expected of a calcimimetic substance.
Estonian: On tõendatud, et ravim on efektiivne parathormoonisisalduse vähendamisel kroonilise neeruhaigusega ja dialüüsravi saavatel patisentidel ning kõrvalnähud on samad kui kaltsimimeetiliste ainete eeldatavad kõvalnähud.
English: Parsabiv is used in patients on haemodialysis (a technique for removing waste products from the blood using a blood filtration machine).
Estonian: Parsabivi kasutatakse patsientidel, kes saavad hemodialüüsravi (teatud verepuhastustehnika, kus verest filtreeritakse jääkained).
English: When cells in the parathyroid gland detect high levels of calcium in the blood, they reduce the amount of parathyroid hormone entering the blood.
Estonian: Kui kõrvalkilpnäärme rakud tuvastavad vere suure kaltsiumisisalduse, eritub vereringesse parathormooni vähem.
English: Reduced parathyroid hormone decreases the levels of calcium in the blood.
Estonian: Vere parathormoonisisalduse vähenemine vähendab vere kaltsiumisisaldust.
English: Parsabiv can only be obtained with a prescription.
Estonian: Parsabiv on retseptiravim.
English: It is given at the end of a haemodialysis session into the line that leads back from the dialysis machine to the patient's vein.
Estonian: Ravimit manustatakse hemodialüüsiseansi lõpus dialüsaatorit patsiendi veeniga ühendavasse kateetrisse.
English: This means that it mimics the action of calcium on these cells and in this way, it reduces the parathyroid hormone levels in the blood.
Estonian: Parsabivi toimeaine etelkaltsetiid on kaltsimimeetiline aine ehk aine, mis imiteerib kaltsiumi toimet nendele rakkudele ja vähendab sellega vere parathormoonisisaldust.
English: Parsabiv is available as a solution for injection.
Estonian: Parsabiv tarnitakse süstelahusena.
English: The other concerns remained.
Estonian: Muud põhjused ettevaatlikkuseks jäid samaks.
English: What is CIMZIA?
Estonian: Mis on CIMZIA?
English: In addition, the Committee was concerned that the company had not demonstrated that it would have been able to monitor the quality of the medicine to an acceptable level.
Estonian: Lisaks ei olnud komitee rahul sellega, et ettevõte ei tõendanud, et ta suudab jälgida ravimi kvaliteeti vastuvõetaval tasemel.
English: In addition, the study of maintenance treatment did not last long enough to give meaningful information on the medicine's long-term effects.
Estonian: Peale selle ei kestnud säilitav ravi piisavalt kaua, et anda asjakohast teavet ravimi pikaajalise toime kohta.
English: It was to be used in patients who had not responded to a full and adequate course of therapy with a corticosteroid or an immunosuppressant medicine (a medicine that reduces the activity of the immune system) or who cannot take these therapies.
Estonian: Seda kavatseti kasutada patsientidel, kes ei reageerinud täielikule ja asjakohasele kortikosteroidiga või immunosupressandiga (immuunvastust vähendava ravimiga) ravikuurile või kes ei talunud sellist ravi.
English: After having considered the grounds for this request, the CHMP re-examined the initial opinion, and confirmed the recommendation for the refusal of the marketing authorisation on 19 March 2008.
Estonian: Pärast taotluse põhjenduste kaalumist vaatas komitee algse arvamuse uuesti läbi ja kinnitas 19. märtsil 2008 soovitust müügiloa andmisest keelduda.
English: The main measure of effectiveness was the proportion of patients whose symptoms had improved or disappeared after six and 26 weeks.
Estonian: Efektiivsuse peamine näitaja oli nende patsientide osakaal, kelle sümptomid olid leevenenud või kadunud pärast 6 ja 26 nädalat.
English: International non-proprietary name (INN): certolizumab pegol
Estonian: Rahvusvaheline mittekaubanduslik nimetus (INN): tsertolisumab-pegool
English: The main measure of effectiveness was the proportion of the patients who were still responding to treatment after 26 weeks.
Estonian: Efektiivsuse peamine näitaja oli nende patsientide osakaal, kes reageerisid ravile ka pärast 26 nädalat.
English: This decreases the rate at which the substance is removed from the body and allows the medicine to be given less often.
Estonian: See suurendab toimeaine püsimist organismis ja võimaldab manustada ravimit harvemini.
English: In March 2008, following the re-examination, the CHMP removed its concern regarding the ability to monitor the medicine's quality.
Estonian: 2008. aasta märtsis võttis komitee pärast taotluse taasläbivaatamist tagasi oma seisukoha ravimi kvaliteedi jälgimise osas.
English: Ref. EMEA/CHMP/145497/2008
Estonian: London, 19. märts 2008 Viitedokument: EMEA/224483/2008
English: The company that applied for authorisation is UCB Pharma SA.
Estonian: Müügiluba taotles ettevõte UCB Pharma SA.
English: A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and bind to a specific structure (called an antigen) that is found in the body.
Estonian: Monoklonaalne antikeha on antikeha (valgu liik), mis on ette nähtud ära tundma organismis leiduvat spetsiifilist struktuuri (mida nimetatakse antigeeniks) ja sellega seonduma.
English: In the study of induction treatment, CIMZIA showed only marginal effectiveness, which was too low to be relevant for patients.
Estonian: Induktsioonravi uuringus oli CIMZIA efektiivsus marginaalne, mis oli patsientidele olulisena olemiseks liiga väike.
English: The second study looked at the maintenance of the medicine's effects in 428 patients who had responded to an initial six-week course of CIMZIA.
Estonian: Teises uuringus vaadeldi ravimi mõju säilitamist 428 patsiendil, kellel oli tekkinud CIMZIA kuuenädalase induktsioonravikuuri vastus.
English: The Committee was also concerned over CIMZIA's safety: although generally comparable with the safety of other medicines in the same class, there was also some concern over a possible increased risk of bleeding in patients receiving CIMZIA.
Estonian: Komitee ei olnud rahul ka CIMZIA ohutusega: kuigi käesoleva ravimi ohutust saab üldiselt võrrelda sama klassi teiste ravimite ohutusega, leiti olevat põhjust ettevaatlikkuseks, sest CIMZIAt saavatel patsientidel võib olla verejooksu suurem risk.
English: It also removed its concern over the possible increased risk of bleeding, but maintained a general concern over CIMZIA's safety.
Estonian: Samuti võttis komitee tagasi seisukoha võimaliku verejooksu suurenenud riski osas, kuid üldine ettevaatlikkus CIMZIA ohutuse kohta jäi endiseks.
English: The first study looked at the reduction of symptoms during ‘induction treatment' in 660 patients who had not received CIMZIA before.
Estonian: Esimeses uuringus vaadeldi sümptomite vähenemist induktsioonravi ajal 660 patsiendil, kes varem ei olnud CIMZIAt saanud.
English: On 15 November 2007, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product CIMZIA 200 mg powder and solvent for solution for injection, intended for the treatment of severe, active Crohn's disease.
Estonian: 15. novembril 2007 võttis inimravimite komitee vastu negatiivse otsuse, soovitades raske aktiivse Crohni tõve raviks kasutatava ravimi CIMZIA (200 mg pulber ja lahusti süstelahuse valmistamiseks) müügiloa andmisest keelduda.
English: In November 2007, the CHMP was concerned that there was insufficient evidence to show a benefit of CIMZIA.
Estonian: 2007. aasta novembris kahtles komitee, kas CIMZIA kasulikkuse kinnitamiseks on piisavalt tõendeid.
English: This messenger is involved in causing inflammation and is found at high levels in patients with active Crohn's disease.
Estonian: See virgatsaine osaleb põletiku tekitamises ja selle sisaldus on suur patsientidel, kes põevad aktiivset Crohni tõbe.
English: It includes certolizumab, which is part of a monoclonal antibody.
Estonian: See sisaldab tsertolisumabi, mis on monoklonaalse antikeha osa.
English: The effectiveness of adding CIMZIA to existing treatment was compared with that of placebo (a dummy treatment) in two main studies involving adults with moderate to severe Crohn's disease.
Estonian: CIMZIA lisamise efektiivsust olemasolevale ravile võrreldi platseebo (näiva ravimi) lisamise efektiivsusega kahes põhiuuringus, milles osalesid keskmise kuni raske Crohni tõvega täiskasvanud.
English: Hence, the CHMP recommended that CIMZIA be refused marketing authorisation.
Estonian: Komitee soovitas seepärast CIMZIA müügiloa andmisest keelduda.
English: Therefore, at that point in time, the CHMP was of the opinion that the benefits of CIMZIA in the treatment of severe, active Crohn's disease did not outweigh its risks.
Estonian: Seetõttu arvas sel ajal inimravimite komitee, et CIMZIA kasulikkus raske aktiivse Crohni tõve ravis ei ületa ravimiga kaasnevaid riske.
English: By blocking TNF-alpha, certolizumab was expected to improve the inflammation and other symptoms of the disease.
Estonian: Eeldati, et TNF-α blokeerimisega leevendab tsertolisumab põletikku ja haiguse muid sümptomeid.
English: It contains the active substance certolizumab pegol.
Estonian: Ravim sisaldab toimeainena tsertolisumab-pegooli.
English: QUESTIONS AND ANSWERS ON RECOMMENDATION FOR THE REFUSAL OF THE MARKETING AUTHORISATION for CIMZIA
Estonian: TEAVE SOOVITUSE KOHTA KEELDUDA ANDMAST MÜÜGILUBA ravimile CIMZIA
English: The company informed the CHMP that there are no consequences for patients currently included in clinical trials or compassionate use programmes with CIMZIA.
Estonian: Ettevõte teatas inimravimite komiteele, et praegu CIMZIA kliinilistes uuringutes või eriloaga kasutamise programmides osalevatele patsientidele tagasivõtmine mõju ei avalda.
English: CIMZIA was expected to be used to treat severe, active Crohn's disease (a disease causing inflammation of the digestive tract).
Estonian: CIMZIAt kavatseti kasutada raske ja aktiivse Crohni tõve (soolepõletikku põhjustav haigus) ravimiseks.
English: What are the consequences of the refusal for patients in clinical trials or compassionate use programmes using CIMZIA?
Estonian: Kuidas mõjutab keeldumine praegu CIMZIA kliinilistes uuringutes või eriloaga kasutamise programmides osalevaid patsiente?
English: The active substance in CIMZIA, certolizumab pegol, is an immunosuppressant medicine.
Estonian: CIMZIAs toimeainena sisalduv tsertolisumab-pegool on immunosupressant (immuunvastust vähendav ravim).
English: CIMZIA is a powder and solvent that is made up into a solution for injection under the skin.
Estonian: CIMZIA on pulber ja lahusti naha alla süstitava süstelahuse valmistamiseks.
English: How is CIMZIA expected to work?
Estonian: Milline on CIMZIA eeldatav toime?
English: The effects of CIMZIA were first tested in experimental models before being studied in humans.
Estonian: Enne inimuuringuid kontrolliti CIMZIA toimet muude katsetega.
English: In CIMZIA, certolizumab has been ‘pegylated' (attached to a chemical called polyethylene glycol).
Estonian: CIMZIAs on tsertolisumab pegüleeritud (kinnitatud keemilise aine polüetüleenglükooli külge).
English: What was CIMZIA expected to be used for?
Estonian: Milleks kavatseti CIMZIAt kasutada?
English: Certolizumab has been designed to bind to a chemical messenger in the body called tumour necrosis factor-alpha (TNF-alpha).
Estonian: Tsertolisumab seondub spetsiifiliselt organismis sisalduva virgatsaine - kasvaja α-nekroositeguriga (TNF-α).
English: An excessive increase, however, occurs only in isolated cases.
Estonian: Ülemäärast suurenemist esineb siiski ainult üksikjuhtudel.
English: Date of first authorisation: 12 June 2009 Date of latest renewal: 21 February 2014
Estonian: Müügiloa esmase väljastamise kuupäev: 12. juuni 2009 Müügiloa viimase uuendamise kuupäev: 21. veebruar 2014
English: If you take CONTROLOC Control for longer periods, this may cause additional risks, such as:
Estonian: Kui te kasutate CONTROLOC Controli pikema aja jooksul, võib see põhjustada täiendavaid riske, näiteks:
English: • They have any other serious disease affecting general well-being.
Estonian: • kui neil on mõni muu tõsine haigus, mis mõjutab nende üldist tervislikku seisundit;
English: The most commonly reported adverse reactions are diarrhoea and headache, both occurring in approximately 1% of patients.
Estonian: Kõige sagedamini täheldatud kõrvaltoimed on kõhulahtisus ja peavalu, mis mõlemad tekivad ligikaudu 1%-l patsientidest.
English: Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.
Estonian: Informeerige oma arsti või apteekrit, kui te kasutate või olete hiljuti kasutanud või kavatsete kasutada mis tahes muid ravimeid.
English: Other medicines and CONTROLOC Control
Estonian: Muud ravimid ja CONTROLOC Control
English: { mm/yyyy}
Estonian: {KK/AAAA}
English: This leaflet was last revised in {mm/yyyy}
Estonian: Infoleht on viimati uuendatud {KK/AAAA}
English: CONTROLOC Control has no or negligible influence on the ability to drive and use machines.
Estonian: CONTROLOC Controlil ei ole või on ebaoluline toime autojuhtimise ja masinate käsitsemise võimele.
English: To avoid this interference, CONTROLOC Control treatment should be stopped for at least 5 days before CgA measurements (see section 5.1).
Estonian: Selle häire vältimiseks tuleb ravi CONTROLOC Controliga lõpetada vähemalt 5 päeva enne CgA määramist (vt lõik 5.1).
English: CONTROLOC Control 20 mg gastro-resistant tablets should not be chewed or crushed, and should be swallowed whole with liquid before a meal.
Estonian: CONTROLOC Control 20 mg gastroresistentseid tablette ei tohi närida ega purustada ning need tuleb sisse võtta tervelt koos veega enne sööki.
English: What you need to know before you take CONTROLOC Control
Estonian: Mida on vaja teada enne CONTROLOC Controli võtmist
English: You must not use CONTROLOC Control if you are taking HIV protease inhibitors.
Estonian: Ärge võtke CONTROLOC Controli, kui te kasutate HIV proteaasi inhibiitoreid.
English: Stop taking CONTROLOC Control when you are completely symptom-free.
Estonian: Lõpetage CONTROLOC Controli võtmine, kui teie sümptomid on täielikult kadunud.
English: Within the following table, adverse reactions are ranked under the MedDRA frequency classification:
Estonian: Alljärgnevas tabelis on kõrvaltoimed esitatud MedDRA esinemissageduse klassifikatsiooni kohaselt:
English: The half-life of the main metabolite (about 1.5 h) is not much longer than that of pantoprazole.
Estonian: Põhimetaboliidi poolväärtusaeg (ligikaudu 1,5 h) ei ole palju pikem kui pantoprasoolil.
English: If possible take your medicine and this leaflet with you
Estonian: Kui võimalik, siis võtke ravim ja see infoleht endaga kaasa.
English: In most patients, freedom from heartburn and acid reflux symptoms is achieved in 1 week.
Estonian: Enamikul patsientidel saavutatakse kõrvetistest ja happerefluksi sümptomitest vabanemine 1 nädala jooksul.
English: Very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000), not known (cannot be estimated from the available data).
Estonian: väga sage (≥ 1/10), sage (≥ 1/100 kuni < 1/10), aeg-ajalt (≥ 1/1000 kuni < 1/100), harv (≥ 1/10 000 kuni < 1/1000), väga harv (< 10 000), teadmata (esinemissagedust ei saa hinnata olemasolevate andmete alusel).
English: What CONTROLOC Control is and what it is used for
Estonian: Mis ravim on CONTROLOC Control ja milleks seda kasutatakse
English: Production site Oranienburg Lehnitzstraße 70-98, 16515 Oranienburg Germany
Estonian: Production site Oranienburg Lehnitzstraße 70-98, 16515 Oranienburg Saksamaa
English: Hallucination; Confusion (especially in pre-disposed patients, as well as the aggravation of these symptoms in case of pre-existence)
Estonian: Hallutsinatsioon; segasus (eelkõige vastava eelsoodumusega patsientidel ning ka nende sümptomite agravatsioon)
English: CONTROLOC Control is available in Alu/Alu blisters with or without cardboard reinforcement.
Estonian: CONTROLOC Control on saadaval Al/Al blisterpakendis koos papist tugevdusega või ilma.
English: As pantoprazole is extensively protein bound, it is not readily dialysable.
Estonian: Kuna pantoprasool seondub ulatuslikult valkudega, siis ei ole see eriti dialüüsitav.
English: Detailed information on this medicine is available on the European Medicines Agency web site: http:// www.ema.europa.eu/.
Estonian: Täpne teave selle ravimi kohta on Euroopa Ravimiameti kodulehel: http://www.ema.europa.eu/.
English: Pharmacotherapeutic group: Drugs for acid related disorders Proton pump inhibitors, ATC code: A02BC02
Estonian: Farmakoterapeutiline rühm: maomahla happesusega seotud häirete raviks kasutatavad ained, prootonpumba inhibiitorid; ATC-kood: A02BC02
English: What CONTROLOC Control contains - The active substance is pantoprazole.
Estonian: Mida CONTROLOC Control sisaldab - Toimeaine on pantoprasool.